{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:58:16Z","timestamp":1783576696155,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Chinese Academy of Medical Science Innovation Fund for Medical Sciences","award":["2021-I2M-1-016"],"award-info":[{"award-number":["2021-I2M-1-016"]}]},{"name":"National High-Level Hospital Clinical Research Funding","award":["2022-PUMCH-C-004"],"award-info":[{"award-number":["2022-PUMCH-C-004"]}]},{"name":"National High-Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-002"],"award-info":[{"award-number":["2022-PUMCH-D-002"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272046"],"award-info":[{"award-number":["82272046"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00259-025-07687-0","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:48:27Z","timestamp":1765327707000},"page":"3064-3073","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["[68Ga]Ga-P16-093 PET\/CT in newly diagnosed prostate cancer: Histopathological validation and comparison with [68Ga]Ga-PSMA-11"],"prefix":"10.1007","volume":"53","author":[{"given":"Jiarou","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingci","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingtong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hank F.","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhien","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7394-9889","authenticated-orcid":false,"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"7687_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"7687_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, et al. NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22:140\u201350. https:\/\/doi.org\/10.6004\/jnccn.2024.0019.","journal-title":"J Natl Compr Canc Netw."},{"key":"7687_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.eururo.2010.12.009","volume":"59","author":"L Dickinson","year":"2011","unstructured":"Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011;59:477\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2010.12.009.","journal-title":"Eur Urol"},{"key":"7687_CR4","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.eururo.2018.11.031","volume":"75","author":"DC Johnson","year":"2019","unstructured":"Johnson DC, Raman SS, Mirak SA, Kwan L, Bajgiran AM, Hsu W, et al. Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging. Eur Urol. 2019;75:712\u201320. https:\/\/doi.org\/10.1016\/j.eururo.2018.11.031.","journal-title":"Eur Urol"},{"key":"7687_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijrobp.2021.03.055","volume":"111","author":"SC Masters","year":"2021","unstructured":"Masters SC, Hofling AA, Gorovets A, Marzella L. FDA approves Ga 68 PSMA-11 for prostate cancer imaging. Int J Radiat Oncol Biol Phys. 2021;111:27\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.055.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7687_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, den Van Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"issue":"10","key":"7687_CR7","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(10):1067\u201396. https:\/\/doi.org\/10.6004\/jnccn.2023.0050.","journal-title":"J Natl Compr Canc Netw"},{"key":"7687_CR8","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","volume":"44","author":"MT Freitag","year":"2017","unstructured":"Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68)Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI. Eur J Nucl Med Mol Imaging. 2017;44:776\u201387. https:\/\/doi.org\/10.1007\/s00259-016-3594-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7687_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-017-0261-8","volume":"7","author":"B Noto","year":"2017","unstructured":"Noto B, B\u00fcther F, der Auf Springe K, Avramovic N, Heindel W, Sch\u00e4fers M, et al. Impact of PET acquisition durations on image quality and lesion detectability in whole-body 68Ga-PSMA PET-MRI. EJNMMI Res. 2017;7:12. https:\/\/doi.org\/10.1186\/s13550-017-0261-8.","journal-title":"EJNMMI Res"},{"key":"7687_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nucmedbio.2017.12.007","volume":"59","author":"Z Zha","year":"2018","unstructured":"Zha Z, Ploessl K, Choi SR, Wu Z, Zhu L, Kung HF. Synthesis and evaluation of a novel urea-based (68)Ga-complex for imaging PSMA binding in tumor. Nucl Med Biol. 2018;59:36\u201347. https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.12.007.","journal-title":"Nucl Med Biol"},{"key":"7687_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s11307-022-01720-6","volume":"24","author":"H Lee","year":"2022","unstructured":"Lee H, Scheuermann JS, Young AJ, Doot RK, Daube-Witherspoon ME, Schubert EK, et al. Preliminary evaluation of (68)Ga-P16-093, a PET radiotracer targeting prostate-specific membrane antigen in prostate cancer. Mol Imaging Biol. 2022;24:710\u201320. https:\/\/doi.org\/10.1007\/s11307-022-01720-6.","journal-title":"Mol Imaging Biol"},{"key":"7687_CR12","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1007\/s00259-023-06283-4","volume":"50","author":"G Wang","year":"2023","unstructured":"Wang G, Li L, Zhu M, Zang J, Wang J, Wang R, et al. A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET\/CT in patients with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50:3126\u201336. https:\/\/doi.org\/10.1007\/s00259-023-06283-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7687_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/rlu.0000000000004566","volume":"48","author":"G Wang","year":"2023","unstructured":"Wang G, Li L, Zang J, Hong H, Zhu L, Kung HF, et al. Head-to-head comparison of 68Ga-P16-093 and 68Ga-PSMA-617 PET\/CT in patients with primary prostate cancer: a pilot study. Clin Nucl Med. 2023;48:289\u201395. https:\/\/doi.org\/10.1097\/rlu.0000000000004566.","journal-title":"Clin Nucl Med"},{"key":"7687_CR14","doi-asserted-by":"publisher","first-page":"48.e1","DOI":"10.1016\/j.urolonc.2022.10.003","volume":"41","author":"CD Bahler","year":"2023","unstructured":"Bahler CD, Green MA, Tann MA, Swensson JK, Collins K, Alexoff D, et al. Assessing extra-prostatic extension for surgical guidance in prostate cancer: Comparing two PSMA-PET tracers with the standard-of-care. Urol Oncol. 2023;41:48.e1-e9. https:\/\/doi.org\/10.1016\/j.urolonc.2022.10.003.","journal-title":"Urol Oncol."},{"key":"7687_CR15","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2967\/jnumed.121.262398","volume":"63","author":"I Sonni","year":"2022","unstructured":"Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, et al. Head-to-head comparison of (68)Ga-PSMA-11 PET\/CT and mpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: results from a prospective single-center imaging trial. J Nucl Med. 2022;63:847\u201354. https:\/\/doi.org\/10.2967\/jnumed.121.262398.","journal-title":"J Nucl Med"},{"key":"7687_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","volume":"84","author":"RA Werner","year":"2023","unstructured":"Werner RA, Hartrampf PE, Fendler WP, Serfling SE, Derlin T, Higuchi T, et al. Prostate-specific membrane antigen reporting and data system version 2.0. Eur Urol. 2023;84:491\u2013502. https:\/\/doi.org\/10.1016\/j.eururo.2023.06.008.","journal-title":"Eur Urol"},{"key":"7687_CR17","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2967\/jnumed.121.263448","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al. The PRIMARY Score: Using Intraprostatic (68)Ga-PSMA PET\/CT Patterns to Optimize Prostate Cancer Diagnosis. J Nucl Med. 2022;63:1644\u201350. https:\/\/doi.org\/10.2967\/jnumed.121.263448.","journal-title":"J Nucl Med"},{"key":"7687_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018;59:469\u201378. https:\/\/doi.org\/10.2967\/jnumed.117.198119.","journal-title":"J Nucl Med"},{"key":"7687_CR19","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3760\/cma.j.cn112151-20210321-00220","volume":"50","author":"X Teng","year":"2021","unstructured":"Teng X. Consensus on specimen handling and pathological diagnosis of prostatic carcinoma (2021 version). Zhonghua Bing Li Xue Za Zhi. 2021;50:994\u20131001. https:\/\/doi.org\/10.3760\/cma.j.cn112151-20210321-00220.","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"7687_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1148\/radiol.09090475","volume":"255","author":"B Turkbey","year":"2010","unstructured":"Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, et al. Prostate cancer: value of multiparametric MR imaging at 3 T for detection\u2013histopathologic correlation. Radiology. 2010;255:89\u201399. https:\/\/doi.org\/10.1148\/radiol.09090475.","journal-title":"Radiology"},{"key":"7687_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. P roc: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77. https:\/\/doi.org\/10.1186\/1471-2105-12-77.","journal-title":"BMC Bioinformatics"},{"key":"7687_CR22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2967\/jnumed.123.266940","volume":"65","author":"J Zang","year":"2024","unstructured":"Zang J, Yang Y, Chen S, Wang C, Chen S, Hu S, et al. Diagnostic performance of [(18)F]AlF-thretide PET\/CT in patients with newly diagnosed prostate cancer using histopathology as reference standard. J Nucl Med. 2024;65:1021\u20136. https:\/\/doi.org\/10.2967\/jnumed.123.266940.","journal-title":"J Nucl Med"},{"key":"7687_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2967\/jnumed.123.266164","volume":"65","author":"L Emmett","year":"2024","unstructured":"Emmett L, Papa N, Counter W, Calais J, Barbato F, Burger I, et al. Reproducibility and accuracy of the PRIMARY score on PSMA PET and of PI-RADS on multiparametric MRI for prostate cancer diagnosis within a real-world database. J Nucl Med. 2024;65:94\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.266164.","journal-title":"J Nucl Med"},{"key":"7687_CR24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1007\/s00259-024-06916-2","volume":"52","author":"S Guo","year":"2025","unstructured":"Guo S, Ren J, Meng Q, Zhang B, Jiao J, Han D, et al. The impact of integrating PRIMARY score or SUVmax with MRI-based risk models for the detection of clinically significant prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52:756\u201365. https:\/\/doi.org\/10.1007\/s00259-024-06916-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7687_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/ju.0000000000004032","volume":"212","author":"CD Bahler","year":"2024","unstructured":"Bahler CD, Tachibana I, Tann M, Collins K, Swensson JK, Green MA, et al. Comparing magnetic resonance imaging and prostate-specific membrane antigen-positron emission tomography for prediction of extraprostatic extension of prostate cancer and surgical guidance: a prospective nonrandomized clinical trial. J Urol. 2024;212:290\u20138. https:\/\/doi.org\/10.1097\/ju.0000000000004032.","journal-title":"J Urol"},{"key":"7687_CR26","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2967\/jnumed.117.195172","volume":"59","author":"N Woythal","year":"2018","unstructured":"Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen JC, Huang K, et al. Immunohistochemical validation of PSMA expression measured by (68)Ga-PSMA PET\/CT in primary prostate cancer. J Nucl Med. 2018;59:238\u201343. https:\/\/doi.org\/10.2967\/jnumed.117.195172.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07687-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07687-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07687-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:26:21Z","timestamp":1774401981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07687-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7687"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07687-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study approved by the Institutional Review Board of Peking Union Medical College Hospital (No. ZS-2461).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants provided written informed consent for the publication of the data collected in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Hank F. Kung is the founder of Five Eleven Pharma, which holds the patent rights for P16-093 and related technology. Prof. Kung was not involved in the collection, analysis, or interpretation of the data. Other authors have no conflicts of interest or relevant financial activities to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}